Global Plasminogen Deficiency Type 1 Market Size is projected to reach USD 821.5 Million by 2035 | CAGR of 4.88%
Category: HealthcareGlobal Plasminogen Deficiency Type 1 Market Size is Projected to Reach USD 821.5 Million by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Plasminogen Deficiency Type 1 Market Size is Expected to Grow from USD 486.5 Million in 2024 to USD 821.5 Million by 2035, at a CAGR of 4.88% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the " Global Plasminogen Deficiency Type 1 Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Plasminogen, Surgery, and Others), By Diagnosis (Physical Exam, Laboratory Test, and Others), By Dosage (Tablet, Injection, and Others), By End-Users (Clinic, Hospital, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/plasminogen-deficiency-type-1-market
The Plasminogen Deficiency Type 1 Market Size refers to the worldwide industry that focuses on treating an ultra-rare genetic disorder (hypoplasminogenemia), which is characterized by fibrin accumulation and ligneous lesions, with Ryplazim (plasminogen, human-tvmh) being the first FDA-approved, primary therapy. Targeted enzyme replacement therapy, prophylaxis and personalized dosing, shifting away from surgery, a multidisciplinary approach, and ongoing research focus are some key trends in the PLGD-1 treatment, which greatly improve the quality of life by preventing the recurrence of tissue-damaging pseudomembranes. An increasing awareness of plasminogen deficiency, enabling the receipt of timely diagnosis and access to appropriate treatment, is anticipated to drive the market demand. Specialized health facilities required for treating PLGD-1, like Hemophilia Treatment Centers, which offer multidisciplinary care and expert knowledge, contribute to escalating the market demand. On the contrary, concerns associated with the treatment cost and accessibility, especially in price-sensitive regions and geographic disparities are challenging the market.
The plasminogen segment dominated the market with the largest share of about 52.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the treatment, the Plasminogen Deficiency Type 1 Market Size is divided into plasminogen, surgery, and others. Among these, the plasminogen segment dominated the market with the largest share of about 52.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. The clinically proven ability of plasminogen for preventing thrombotic events, its targeted mechanism, and established efficacy are responsible for propelling the market.
The laboratory test segment accounted for the largest share of nearly 48.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the diagnosis, the Plasminogen Deficiency Type 1 Market Size is divided into physical exam, laboratory test, and others. Among these, the laboratory test segment accounted for the largest share of nearly 48.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Specialized laboratory test reveals significantly reduced functional plasminogen activity of less than 45% and concordantly low antigenic levels of less than 50, which confirms the diagnosis of plasminogen deficiency type 1.
The injection segment held the largest market share of about 60.1% in 2024 and is anticipated to grow at a significant CAGR during the projected period.
Based on the dosage, the Plasminogen Deficiency Type 1 Market Size is divided into tablet, injection, and others. Among these, the injection segment held the largest market share of about 60.1% in 2024 and is anticipated to grow at a significant CAGR during the projected period. PLGD-1 is managed with FDA-approved IV human-derived plasminogen (Rylazim), usually intravenous infusions of 6.6 mg/kg (often every 2-4 days), enabling direct replacement of the deficient enzyme to reverse the underlying cause of disease-related fibrin lesions.
The hospital segment dominated the market with the largest share of around 65.0% in 2024 and is anticipated to grow at a substantial CAGR during the projected period.
Based on the end-users, the Plasminogen Deficiency Type 1 Market Size is divided into clinic, hospital, and others. Among these, the hospital segment dominated the market with the largest share of around 65.0% in 2024 and is anticipated to grow at a substantial CAGR during the projected period. The segment includes advanced infrastructure, specialized care units, and highly trained healthcare professionals. The availability of multidisciplinary teams of hematologists, geneticists, and specialists in rare diseases in hospitals is propelling the market.
Get more details on this report -
North America is expected to hold the majority share of the global Plasminogen Deficiency Type 1 Market Size during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 43.3% in the global Plasminogen Deficiency Type 1 Market Size during the forecast period. United States is leading the regional market, captured largest share in North America in 2024, owing to the rapid adoption of advanced therapeutic options and investment in specialized clinics, and expanding diagnostic and monitoring facilities. North America has a robust market ecosystem that includes launch of FDA-approved treatment via expanding partnerships. Further, the region's increased diagnostic rates for rare genetic diseases and high healthcare expenditure are responsible for propelling the market growth.
Asia Pacific is anticipated to grow at the fastest pace of CAGR 6.2% in the global Plasminogen Deficiency Type 1 Market Size during the forecast period. India accounts for the dominant market share in the Asia Pacific region, owing to the expanding healthcare infrastructure and the adoption of genetic testing. In the Asia Pacific Plasminogen Deficiency Type 1 Market Size, the company’s widespread adoption of advanced digital technologies and investments in innovation and product development plays important role. Implementation of programs promoting ophthalmology health contributes to supporting the Plasminogen Deficiency Type 1 Market Size.
Major vendors in the global Plasminogen Deficiency Type 1 Market Size are Grifols S.A., Kedrion, Soleo Health, Liminal BioSciences Inc., and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In May 2025, Kedrion Biopharma is raising awareness for Plasminogen Deficiency (PLGD-1) with virtual, digital and in person events throughout the day.
- In May 2024, Soleo Health, an innovative leader and national provider of complex specialty pharmacy services for treating rare and ultra rare diseases, announced it has been named a limited distribution specialty pharmacy partner to dispense RYPLAZIM.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Plasminogen Deficiency Type 1 Market Size based on the below-mentioned segments:
Global Plasminogen Deficiency Type 1 Market Size, By Treatment
- Plasminogen
- Surgery
- Others
Global Plasminogen Deficiency Type 1 Market Size, By Diagnosis
- Physical Exam
- Laboratory Test
- Others
Global Plasminogen Deficiency Type 1 Market Size, By Dosage
- Tablet
- Injection
- Others
Global Plasminogen Deficiency Type 1 Market Size, By End-Users
- Clinic
- Hospital
- Others
Global Plasminogen Deficiency Type 1 Market Size, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?